Welcome to our dedicated page for OneMedNet SEC filings (Ticker: ONMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OneMedNet Corporation (NASDAQ: ONMD) SEC filings page on Stock Titan provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into OneMedNet’s corporate governance, capital structure, and public company obligations as it operates its iRWD™ Real-World Data platform and related services.
Among the key documents, investors can review OneMedNet’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe the company’s business, risk factors, and financial condition. Definitive proxy statements on Schedule 14A, such as the 2025 proxy, outline matters submitted to stockholders, including director elections, auditor ratification, and information about the annual meeting format and voting procedures. These materials also explain how stockholders of record and beneficial owners can participate in the company’s virtual annual meetings.
Current reports on Form 8-K are particularly important for tracking material events affecting ONMD. In 2025, for example, OneMedNet filed 8-Ks describing Nasdaq listing compliance updates related to the minimum bid price and market value of listed securities requirements, as well as board-related matters. Such filings help investors understand how the company is addressing exchange listing standards and corporate governance changes.
On Stock Titan, OneMedNet’s filings are updated as new documents are posted to the SEC’s EDGAR system. AI-powered summaries can assist readers by highlighting the main points of lengthy filings, such as changes in listing status, significant agreements, or governance proposals, while links to specific forms—10-K, 10-Q, 8-K, and DEF 14A—allow deeper review of the underlying disclosures.
OneMedNet Corp director reports no beneficial ownership on Form 3
OneMedNet Corp director filed an initial ownership report stating that no securities of the company are beneficially owned. The filing is made by a single reporting person in the capacity of director, and both the non-derivative and derivative security tables are effectively empty. A remark clarifies that no securities are beneficially owned, and a power of attorney authorizes the attorney-in-fact to sign the form on the reporting person’s behalf.
OneMedNet Corp reported an initial insider ownership filing on Form 3 for a director, with an event date of 02/25/2025. The filing indicates that no securities of OneMedNet Corp are beneficially owned by this reporting person. The form is filed by a single reporting person and is signed by an attorney-in-fact under a power of attorney.
OneMedNet Corp director reports no beneficial ownership on Form 3
A newly reported director of OneMedNet Corp (ONMD) has filed an initial statement of beneficial ownership on Form 3 for an event dated 10/01/2024. The filing identifies the reporting person’s relationship to the company as a Director and confirms that the form is filed by one reporting person only.
In the remarks section, the filing states that no securities are beneficially owned. A Power of Attorney (Exhibit 24) is noted, and the form is signed by an attorney-in-fact on 11/26/2025, documenting that, as of the reported event date, the director does not hold OneMedNet securities in either direct or indirect form.
OneMedNet Corporation filed Prospectus Supplement No. 2 to its Form S-1, registering a primary offering of up to 11,500,000 shares of common stock and a secondary offering of up to 28,152,560 shares for resale. The supplement updates the prospectus dated July 24, 2025 and attaches the company’s Q3 2025 Form 10-Q for the quarter ended September 30, 2025.
The company is an emerging growth company and notes that investing in its securities involves a high degree of risk, directing readers to the Risk Factors section of the prospectus. As context, shares outstanding were 51,005,205 as of November 7, 2025. The supplement must be read together with the base prospectus, and neither the SEC nor any state commission has approved or disapproved the securities.
OneMedNet Corporation reported Q3 2025 results with total revenue of $177K (vs. $142K a year ago), driven by web imaging revenue of $177K as subscription revenue was $0. Gross margin was -$222K, and operating loss was $2.24M. Net loss for the quarter was $741K (vs. $2.06M loss a year ago).
For the nine months, revenue was $468K (vs. $617K in 2024). Despite a $6.59M operating loss, the company recorded $339K net income, primarily from non-operating items, including gains on troubled debt restructurings. Cash was $149K with $600K in Bitcoin (5 units) as of September 30, 2025; total assets were $1.51M against current liabilities of $5.01M, and stockholders’ deficit was -$3.94M. Management states these conditions raise substantial doubt about the ability to continue as a going concern.
The company raised capital through June and August 2025 equity sales and related-party subscriptions, converted debt to equity (PIPE Notes and loan extensions), and repaid the Yorkville note after several conversions. Shares outstanding were 51,005,205 as of November 7, 2025.
OneMedNet Corporation will hold its 2025 Annual Meeting on December 17, 2025 at 11:00 a.m. CT via live audio webcast at https://www.cstproxy.com/onemednet/2025. Stockholders will vote to elect two Class II directors for three-year terms and to ratify WithumSmith+Brown, PC as independent auditor for 2025.
Holders of record on October 23, 2025 may vote; there were 51,157,069 shares of common stock outstanding as of that date. The Board recommends voting FOR both director nominees and FOR auditor ratification. Director Jair Clarke will not stand for re-election; the Board size will be reduced to eight after the meeting.
The Audit Committee reports Withum fees of $840,000 for 2024 (including $790,000 audit and $50,000 tax). BF Borgers was dismissed in May 2024 following an SEC order; its 2023 report included a going concern explanatory paragraph and noted material weaknesses, with no disagreements reported.
Executive updates include RSU awards to leadership and related-party financings and conversions in 2025 involving Dr. Thomas Kosasa and Dr. Jeffrey Yu. As of October 23, 2025, beneficial ownership includes Dr. Kosasa at 30.8% and Dr. Yu at 13.8%.
OneMedNet Corporation announced that director Jair Clarke will not stand for re-election at the Company’s 2025 Annual Meeting of Stockholders. The Company stated his decision was not due to any disagreement with the Company or management. Mr. Clarke will remain on the Board until the Annual Meeting and will continue to serve in an advisory capacity thereafter.
OneMedNet Corporation reported that it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq staff notified the company that, for 10 consecutive business days from September 24, 2025 through October 7, 2025, the closing bid price of its common stock was at least $1.00 per share, satisfying Nasdaq Listing Rule 5550(a)(2). With this notice, the prior bid price deficiency has been resolved and the listing compliance matter is now closed.
OneMedNet Corporation has regained compliance with Nasdaq’s continued listing standards. The company previously received a notice on March 12, 2025 stating that its market value of listed securities had fallen below the required $35,000,000 threshold under Nasdaq Listing Rule 5550(b)(2).
Nasdaq staff has now notified OneMedNet that for 10 consecutive business days, from August 27, 2025 to September 10, 2025, the company’s market value of listed securities was at or above $35,000,000. As a result, OneMedNet is again in compliance with Nasdaq Listing Rule 5550(b)(2), and Nasdaq considers the matter closed, allowing its common stock and warrants to remain listed on The Nasdaq Capital Market.